TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03199482

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Oral Tablet
Description: single dose of tablet 0.5 mg dexamethasone given to patients before starting of root canal treatment by 30 minutes or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administrated 30 minutes before start of root canal treatment
Study: NCT01249924

Intervention type: DEVICE
Group type: OTHER
Intervention: auto-titrated CPAP
Description: Patients will be treated with auto-CPAP preoperatively for 2-3 nights preoperatively and 5 nights postoperatively during their sleep.

Intervention type: DEVICE
Group type: OTHER
Intervention: auto-titrated CPAP
Description: Patients will be treated with auto-CPAP preoperatively for 2-3 nights preoperatively and 5 nights postoperatively during their sleep.

Intervention type: DEVICE
Group type: OTHER
Intervention: Control
Description: Patients in this group will receive routine care, undergo sleep study on the third postoperative night and be monitored by a pulse oximeter for oxygen saturation level for 2-3 nights preoperatively and 5 nights postoperatively during their sleep.
Study: NCT00006007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Study: NCT02347891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Randomized phase: Week 0 - Week 40

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Randomized phase: Week 0 - Week 40
Study: NCT03207542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: 16 mg/kg by vein weekly for the first 2 cycles (8 weeks) of treatment, followed by every 2 weeks for 4 cycles (or 16 weeks) and then every 4 weeks until progression or up to 1 year of treatment whichever comes earlier.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: 16 mg/kg by vein weekly for the first 2 cycles (8 weeks) of treatment, followed by every 2 weeks for 4 cycles (or 16 weeks) and then every 4 weeks until progression or up to 1 year of treatment whichever comes earlier.
Study: NCT05195684

Intervention type: OTHER
Group type: OTHER
Intervention: imaginal probe
Description: trauma and nightmare imaginal probe/challenge for which psychophysiological and CNS responses are recorded
Study: NCT01047826

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Plate Osteosynthesis
Description: Fractures well be treated with locked plates using M.I.P.O. Technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intramedullary tibial Nailing
Description: Fractures well be fixed using intramedullary nails
Study: NCT02977325

Intervention type: OTHER
Intervention: water cure

Intervention type: OTHER
Intervention: water cure
Study: NCT05246059

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olfactory Training
Description: Sniffin' Sticks (Duft-Quartett, Burghart Messtechnik, GmbH, Germany)
Study: NCT01335074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus + Sorafenib
Description: 200mg bid Sorafenib + 15, 20 or 25 mg Temsirolimus
Study: NCT00070382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darbepoetin alfa
Description: darbepoetin alfa administered at a dose of 200ug once every 2 weeks over a 16-week treatment period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epoetin alfa
Description: epoetin alfa administered at a dose of 40,000U once every week over a 16-week treatment period
Study: NCT05167370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifostine
Description: Amifostine (Ethyol) 1125 mg/m2 will be given intravenously daily over 5 minutes starting 30 minutes prior to chemotherapy (melphalan or thiotepa) on days -5, -4, -3, -2, and on day -1 twenty four hours after prior dose of amifostine.
Study: NCT04749654

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Salivary pH measured
Description: The saliva samples were obtained at 10-12 a.m. from all children. The saliva was collected into plastic cylinders and the salivary pH was measured with a pH meter (Compact pH meter B-212 twin pH, HORIBA, Osaka, Japan).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Salivary pH measured
Description: The saliva samples were obtained at 10-12 a.m. from all children. The saliva was collected into plastic cylinders and the salivary pH was measured with a pH meter (Compact pH meter B-212 twin pH, HORIBA, Osaka, Japan).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The saliva flow rate was measured
Description: The saliva flow rate was estimated by during the first 30 s of paraffin chewing. The saliva was collected into plastic cylinders for a period of 5 minutes. Afterward, the saliva were weighed with a in a precision balance (Mettler PC 400, Zurich, Switzerland) and the flow rate was computed in gms/ml.
Study: NCT02636751

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Walking aid adjustment
Description: Walking aid adjustment
Study: NCT04749654

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The saliva flow rate was measured
Description: The saliva flow rate was estimated by during the first 30 s of paraffin chewing. The saliva was collected into plastic cylinders for a period of 5 minutes. Afterward, the saliva were weighed with a in a precision balance (Mettler PC 400, Zurich, Switzerland) and the flow rate was computed in gms/ml.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Streptococcus mutans and Lactobacillus counts in saliva were measured
Description: The saliva samples were obtained according to described above. Numbers of colony-forming units (CFU) of S. mutans were counted on TSY20B agar and Lactobacilli were counted on Rogosa agar.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Streptococcus mutans and Lactobacillus counts in saliva were measured
Description: The saliva samples were obtained according to described above. Numbers of colony-forming units (CFU) of S. mutans were counted on TSY20B agar and Lactobacilli were counted on Rogosa agar.
Study: NCT03046901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Vancomycin belongs to the family of medicines called antibiotics.When taken by mouth, is used to treat Clostridium difficile-associated diarrhea (also called C diff). C diff is a type of bacteria that causes severe diarrhea. Oral Vancomycin is also used to treat enterocolitis caused by a certain bacteria (e.g., Staphylococcus aureus). Subjects enrolled in the study will take 500 mg capsule, 3 times per day for 3-12 weeks.
Study: NCT00471718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-751
Description: Phase I:~Cohort \| Number of Patients \|Dose (mg) ABT-751 (BID)~* -1 \| 3-6 \|100 mg BID~* 1 \| 3-6 \|125 mg BID~* 2 \| 3-6 \|150 mg BID~* 3 \| 3-6 \|175 mg BID~* 4 \| 3-6 \|200 mg BID~Phase II:~Patients receive ABT-751 at 125mg po BID for 7 days on, 7 days off (X2) for a 28 day cycle
Study: NCT01990196

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: degarelix
Description: Every 4-week Treatment: A starting dose of 240 mg of Degarelix is taken subcutaneously (SQ) -placed under the skin by injection- the first month. Doses continue every 4 weeks at 80 mg SQ.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: degarelix
Description: Every 4-week Treatment: A starting dose of 240 mg of Degarelix is taken subcutaneously (SQ) -placed under the skin by injection- the first month. Doses continue every 4 weeks at 80 mg SQ.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: degarelix
Description: Every 4-week Treatment: A starting dose of 240 mg of Degarelix is taken subcutaneously (SQ) -placed under the skin by injection- the first month. Doses continue every 4 weeks at 80 mg SQ.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enzalutamide
Description: Once Daily Treatment: A starting dose of 160 mg of Enzalutamide is taken by mouth once daily.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enzalutamide
Description: Once Daily Treatment: A starting dose of 160 mg of Enzalutamide is taken by mouth once daily.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enzalutamide
Description: Once Daily Treatment: A starting dose of 160 mg of Enzalutamide is taken by mouth once daily.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trametinib
Description: Once Daily Treatment: If randomized into Group 2, then 2mg of Trametinib is taken by mouth daily.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dasatinib
Description: Once Daily Treatment: If randomized into Group 3, then 100mg of Dasatinib is taken by mouth daily.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician
Study: NCT02877394

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Squatting Assist Device
Description: The Squatty Potty is a 7 inch tall stool to assist subjects in maintaining a squatting position while using a toilet. While sitting on the toilet, the subject supports her feet on the Squatty Potty.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Squatting Assist Device
Description: This stool will be 2 inches tall and be similar in appearance to the Squatty Potty. While sitting on the toilet, the subject supports her feet on the 2 inch high stool.
Study: NCT03898479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543
Description: Twice daily dosing
Study: NCT04158882

Intervention type: OTHER
Intervention: Routine medical record data collection
Description: The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.

Intervention type: OTHER
Intervention: Routine medical record data collection
Description: The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
Study: NCT01613222

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse oximetry
Description: Pulse oximetry measurement using SpO2 sensors, patient monitors, co-oximeters, and various modules.
Study: NCT01976364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Tofacitinib 5 mg tablet twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Tofactinib 10 mg tablet twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate 7.5-20 mg weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Methotrexate
Description: Placebo to match active methotrexate orally once a week
Study: NCT03839290

Intervention type: PROCEDURE
Intervention: Early neonatal cheiloplasty

Intervention type: PROCEDURE
Intervention: Early neonatal cheiloplasty
Study: NCT01556568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Study: NCT03624062

Intervention type: DRUG
Group type: OTHER
Intervention: MAS-1 adjuvanted Insulin B-chain
Description: MER3101 (MAS-1 adjuvanted insulin B chain (IBC)), is a white, free-flowing 30:70 (w/w) water-in-oil (W/O) emulsion. MER3101 contains in the aqueous (disperse) phase 33, 109, or 327 µg per 0.25 mL dose of IBC (Drug Substance) and the oil (continuous) phase is comprised of MAS-1 oil vehicle.

Intervention type: DRUG
Group type: OTHER
Intervention: MAS-1 adjuvanted Insulin B-chain
Description: MER3101 (MAS-1 adjuvanted insulin B chain (IBC)), is a white, free-flowing 30:70 (w/w) water-in-oil (W/O) emulsion. MER3101 contains in the aqueous (disperse) phase 33, 109, or 327 µg per 0.25 mL dose of IBC (Drug Substance) and the oil (continuous) phase is comprised of MAS-1 oil vehicle.

Intervention type: DRUG
Group type: OTHER
Intervention: MAS-1 adjuvanted Insulin B-chain
Description: MER3101 (MAS-1 adjuvanted insulin B chain (IBC)), is a white, free-flowing 30:70 (w/w) water-in-oil (W/O) emulsion. MER3101 contains in the aqueous (disperse) phase 33, 109, or 327 µg per 0.25 mL dose of IBC (Drug Substance) and the oil (continuous) phase is comprised of MAS-1 oil vehicle.

Intervention type: DRUG
Group type: OTHER
Intervention: MAS-1 adjuvanted Insulin B-chain
Description: MER3101 (MAS-1 adjuvanted insulin B chain (IBC)), is a white, free-flowing 30:70 (w/w) water-in-oil (W/O) emulsion. MER3101 contains in the aqueous (disperse) phase 33, 109, or 327 µg per 0.25 mL dose of IBC (Drug Substance) and the oil (continuous) phase is comprised of MAS-1 oil vehicle.
Study: NCT03896737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab plus Velcade Cyclophosphamide Dexamethasone
Description: To compare Dara-VCd versus VTd as pre transplant induction and post transplant consolidation, both followed by a maintenance phase with Ixazomib alone or in combination with Daratumumab, in newly diagnosed Multiple Myeloma (MM) young patients eligible for autologous stem cell transplantation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Velcade Thalidomide Dexamethasone
Description: To compare Dara-VCd versus VTd as pre transplant induction and post transplant consolidation, both followed by a maintenance phase with Ixazomib alone or in combination with Daratumumab, in newly diagnosed Multiple Myeloma (MM) young patients eligible for autologous stem cell transplantation.
Study: NCT05887570

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: intervention through extra education, modules, instruction on models

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control - Regular Instruction
Description: participants receive usual training
Study: NCT02000336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: To compare two standard p.o. GC starting dosages and the non-use of GCs in the treatment of patients with early active RA on the background of the established 'anchor' therapy with methotrexate (MTX).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: To compare two standard p.o. GC starting dosages and the non-use of GCs in the treatment of patients with early active RA on the background of the established 'anchor' therapy with methotrexate (MTX).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01937910

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TRAIT Task
Description: Increased paretic arm will be manipulated through the performance of a semi-immersive virtual reality-based intercept and release task called TRAIT (TRack And Intercept Task), which is performed in an interactive environment. TRAIT employs an open source Kinect sensor, which tracks 3-D joint movement. Participants are asked to control an on-screen icon using movements of their paretic arm to intercept a moving object as it emerges from the side of a computer screen. Once intercepted, they must accurately throw the object to hit a target. Participants move up through 10 levels of the game as their skill improves. Participants will complete 10 TRAIT training sessions in 4 weeks for a total of 10,000 experimental movements.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRAIT Task
Description: Increased paretic arm will be manipulated through the performance of a semi-immersive virtual reality-based intercept and release task called TRAIT (TRack And Intercept Task), which is performed in an interactive environment. TRAIT employs an open source Kinect sensor, which tracks 3-D joint movement. Participants are asked to control an on-screen icon using movements of their paretic arm to intercept a moving object as it emerges from the side of a computer screen. Once intercepted, they must accurately throw the object to hit a target. Participants move up through 10 levels of the game as their skill improves. Participants will complete 10 TRAIT training sessions in 4 weeks for a total of 10,000 experimental movements.
Study: NCT04995250

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: corrective exercise training for knee
Description: All patients received 12 weeks (3 days per week) physiotherapy sessions with hot pack, TENS and Ultrasound session for 10 mints and knee isometric, quad strengthening, adductor and abductor strengthening, calf stretch, hamstring stretch, Maitland mobilization, Unconventional Corrective knee exercise protocol treatment: standing on one extremity, up and down on bosu exercise, walking to lateral direction, walking to anterio-posterior direction, walking to anterio-posterior and lateral for 20 mints. Data were collected at baseline, at week 4 and at post treatment (week 12).
Study: NCT02912260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGL-3196

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02209142

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: blood prelevement
Description: blood sample will be done at the inclusion then at T 2 weeks, T8 weeks, T30weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood prelevement
Description: blood sample will be done at the inclusion then at T 2 weeks, T8 weeks, T30weeks

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: psychometric data collection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychometric data collection
Study: NCT02180984

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS
Description: Transcranial Magnetic Stimulation has developed into a powerful tool that utilizes magnetic fluxes to non-invasively stimulate the human cortex. The technique involves placement of a small coil over the scalp; passing a rapidly alternating current through the coil wire, which produces a magnetic field that passes unimpeded through the scalp and bone, resulting in electrical stimulation of the cortex.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TMS
Description: Transcranial Magnetic Stimulation has developed into a powerful tool that utilizes magnetic fluxes to non-invasively stimulate the human cortex. The technique involves placement of a small coil over the scalp; passing a rapidly alternating current through the coil wire, which produces a magnetic field that passes unimpeded through the scalp and bone, resulting in electrical stimulation of the cortex.
Study: NCT02636751

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Walking aid adjustment
Description: Walking aid adjustment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Walking aid adjustment
Description: Walking aid adjustment
Study: NCT01070095

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Asthma Action Plan System
Description: The electronic asthma action plan system consists of a tablet device in the physician waiting room which participants use to complete a simple questionnaire, a computerized clinical decision support system which then processes these data to produce a set of asthma care recommendations for the clinician, and finally, a printable asthma action plan that is given to patients, along with the URL for an asthma education website.
Study: NCT02350686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: XELOX every 3 weeks will be continued until disease progression, patients' refusal or upto 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: XELOX every 3 weeks will be continued until disease progression, patients' refusal or upto 8 cycles
Study: NCT03781258

Intervention type: DRUG
Group type: OTHER
Intervention: Warfarin
Description: Anti-thrombotic monotherapy (ASA)-Warfarin withdrawal.
Study: NCT02647970

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PUFA-Cys/Met diet
Description: Provision of food and supplements that are rich in polyunsaturated fatty acids (PUFA, n-3 and n-6) and low in the amino acids cysteine (Cys) and methionine (Met).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SFA+Cys/Met diet
Description: Provision of food and supplements that are rich in saturated fatty acids (SFA) and the amino acids cysteine (Cys) and methionine (Met).
Study: NCT00927511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant 500 mg days 0, 14, 28, then 250 mg every 2 weeks for 5 administrations, then 250 mg every 28 days, until progression or unacceptable toxicity vs Fulvestrant 250 mg every 28 days until progression or unacceptable toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant 500 mg days 0, 14, 28, then 250 mg every 2 weeks for 5 administrations, then 250 mg every 28 days, until progression or unacceptable toxicity vs Fulvestrant 250 mg every 28 days until progression or unacceptable toxicity
Study: NCT02212990

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen Arm
Description: Blinded Therapy
Study: NCT02636751

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information about pain control
Description: General information about pain control, such as ice application and medication usage

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information about pain control
Description: General information about pain control, such as ice application and medication usage

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information about pain control
Description: General information about pain control, such as ice application and medication usage
Study: NCT02212990

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Arm
Description: Blinded Therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen Arm
Description: Open Label Therapy
Study: NCT02339350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose methotrexate
Description: HD-MTX IV 5,000 mg/m2 I.V. over 4hr on day 0, 14, 28, 42 of SER interim maintenance schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal triple chemotherapy
Description: Intrathecal triple chemotherapy for SEG group instead of radiotherapy